Intuitive Surgical (NASDAQ: ISRG) has generated significant attention in the investment community, particularly due to its recent stock price decline of approximately 30% since the beginning of 2026. The company, well-known for its da Vinci surgical robot system, presents a unique investment proposition that may not align with the preferences of all types of investors.
Unlike many companies that distribute dividends, Intuitive Surgical does not offer any returns to shareholders in that form, making it less appealing for income investors. Additionally, the stock is considered expensive with a price-to-earnings ratio (P/E) of 51x, which falls short of the lower valuations typically favored by value investors. Instead, it mainly attracts growth investors who are willing to take on more risk for the potential of higher returns.
Despite the price drop, Intuitive Surgical’s fundamentals appear strong. In the first quarter of 2026, the company reported a 12% increase in the number of da Vinci systems installed globally, bringing the total to 11,395 units. Furthermore, there was a notable 17% year-over-year rise in the number of procedures performed using the da Vinci system, indicating robust demand for robotic-assisted surgeries and showcasing a healthy market presence for Intuitive Surgical.
Interestingly, only about 25% of the company’s revenue is derived from the sales of the da Vinci systems themselves. The remaining income comes from instruments, accessories, and services associated with the use of the robots. This creates an annuity-like revenue stream, benefiting from each new installation as well as the ongoing demand for robotic surgery solutions. The continued evolution of the da Vinci system and its regulatory approvals for additional surgical applications further enhance its long-term growth prospects.
Historical performance also provides context for the current situation. Intuitive Surgical’s stock has experienced similar declines in the past, having dropped by 30% or more on eight occasions since its public listing. Each time, the stock eventually rebounded, often reaching new heights afterward. While it’s uncertain if the current drop will follow the same pattern, historical data suggests that these downturns have been temporary.
Investors contemplating entering into a position with Intuitive Surgical face the challenge of maintaining confidence in the company’s unwavering business strength despite market volatility. The sales of new systems remain strong, bolstered by the increasing demand for robotic surgeries. Even if the growth rate of new system sales moderates, the established installed base of da Vinci systems is likely to keep generating substantial revenue.
With its strong fundamentals intact, some analysts posit that the recent stock downturn could represent a rare buying opportunity for growth investors. However, potential investors are encouraged to consider insights from expert analysts. For instance, The Motley Fool’s Stock Advisor team has recommended a list of stocks for consideration, although Intuitive Surgical was not included in their current top picks.
For investors looking to navigate the complexities of stock selection, resources like Stock Advisor, known for its impressive average returns compared to the broader market, may provide valuable guidance. Overall, while Intuitive Surgical presents a promising scenario based on operational metrics, investors must weigh the risks and historical context carefully before making investment decisions.
